Been fully validated for use in clinical practice. The Illumina NGS technology is used in many laboratories but its ability to predict HIV-1 tropism has not been evaluated while the 454 GS-Junior (Roche) is used for routine diagnosis. The genotypic prediction of HIV-1 tropism is based on sequencing the V3 region and interpreting the results with an appropriate algorithm. We compared the performanc
Nts in clinical practice but technical optimization are needed to improve quantification. Human immunodeficiency virus (HIV) enters its host cells following the interaction between the virus envelope glycoprotein (Gp120), the cell surface CD4 receptor, and a chemokine receptor, which may be CCR5 and/ or CXCR4, acting as a coreceptor1. The HIV tropism is defined by the coreceptor(s) use and is corr
Nts in clinical practice but technical optimization are needed to improve quantification. Human immunodeficiency virus (HIV) enters its host cells following the interaction between the virus envelope glycoprotein (Gp120), the cell surface CD4 receptor, and a chemokine receptor, which may be CCR5 and/ or CXCR4, acting as a coreceptor1. The HIV tropism is defined by the coreceptor(s) use and is corr
Anti-HIV therapeutic levels in the CNS.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptDISCUSSIONEffective CNS delivery of many drugs, especially hydrophilic and negatively charged molecules, still remains an unsolved dilemma. Progress of nanotechnology and development of novel particulate drug delivery systems resulted in the extensive search for drug nanoformulations th
Anti-HIV therapeutic levels in the CNS.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptDISCUSSIONEffective CNS delivery of many drugs, especially hydrophilic and negatively charged molecules, still remains an unsolved dilemma. Progress of nanotechnology and development of novel particulate drug delivery systems resulted in the extensive search for drug nanoformulations th
Ion sequencing platforms for determining HIV-1 coreceptor useSt hanie Raymond1,2,3, Florence Nicot3, Nicolas Jeanne3, Olivier Delfour3, Romain Carcenac3, Caroline Lefebvre3, Michelle Cazabat1,3, Karine Saun?,2,3, Pierre Delobel1,2,4 Jacques Izopet1,2,The coreceptor used by HIV-1 must be determined before a CCR5 antagonist, part of the arsenal of antiretroviral drugs, is prescribed because viruse
He differences between the paired measurements plotted against their means) of samples containing X4 variants obtained with MiSeq and 454 GS-Junior systems was used to assess graphically the magnitude of disagreement between the methods and estimate the overall bias. A Spearman's correlation coefficient was used to assess the strength of linear association between the methods for quantifying X4 va
He differences between the paired measurements plotted against their means) of samples containing X4 variants obtained with MiSeq and 454 GS-Junior systems was used to assess graphically the magnitude of disagreement between the methods and estimate the overall bias. A Spearman's correlation coefficient was used to assess the strength of linear association between the methods for quantifying X4 va